mdxhealth Collaboration with Oxford could further validate GPS in prostate cancer

Yesterday before US market opens, mdxhealth announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomised clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progression and long-term treatment outcomes. According to management, data publication is expected in 2026/2027, and no competitor has such evidence in patients being considered for Active Surveillance. We expect this to be supportive for GPS in gaining market share and could help expand the market by further demonstrating the utility of such tests. $ 4.2 TP and BUY maintained.